Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase 2/3 1Phase 1/2 1

Status

Completed 22Terminated 3Recruiting 3Active not recruiting 3Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Dermatologic 1CNS 1

Conditions

Breast Neoplasms 2Meningioma 1Melanoma 1

Interventions

Cyclophosphamide 119Specimen Handling 104pembrolizumab 102Magnetic Resonance Spectroscopy 96fludarabine 92Biopsy 79Injections 53Nivolumab 41venetoclax 40Bevacizumab 40Fluorouracil 38Paclitaxel 37Cisplatin 36Cetuximab 35Carboplatin 35Gemcitabine 31fludarabine phosphate 30Radiotherapy 30Oxaliplatin 30Leucovorin 28Immunotherapy, Adoptive 25Drug Therapy 25Ipilimumab 24Azacitidine 23Irinotecan 21130-nm albumin-bound paclitaxel 21tislelizumab 20Temozolomide 20Radiation 20atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Alpelisib × Clear all
NCT06545682 2026-04-16

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

M.D. Anderson Cancer Center

Phase 1 Recruiting
50 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

NCT05508906 2025-10-22

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Olema Pharmaceuticals, Inc.

Phase 1 Recruiting
190 enrolled
Breast

Breast Neoplasms

NCT03631953 2024-08-06

ALTREM

Assistance Publique Hopitaux De Marseille

Phase 1 Recruiting
25 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡